Abstract 5399
Background
In the new era of precision medicine, identifying clinical or molecular factors that predict benefit of immune checkpoint inhibitors is crucial to prevent patients from autoimmune adverse effects and high cost of such agents.
Methods
We conducted this meta-analysis on the basis of the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) statement. Two reviews independently completed a search of PubMed and Web of science to identify relevant clinical trials. The search was conducted using keywords “nivolumab”, “pembrolizumab”, “atezolizumab” and “immune checkpoint”. The search was limited to randomized controlled trails (RCTs) published in English.
Results
Eleven eligible studies, including 5,663 patients, were included in this meta-analysis. In our analysis, PD-1/PD-L1 inhibitor was associated with a 31% reduction in the risk of death (HR = 0.69; 95%CI, 0.64-0.74; P < 0.00001). In subgroup analysis, patients got overall survival (OS) benefit from PD-1/PD-L1 inhibitors regardless of PD-L1 expression, and a dose effect relationship between expression of PD-L1 and OS benefit from PD-1/PD-L1 inhibitors was observed (Interaction, P < 0.00001). Patients with smoking history achieved greater OS benefits (HR = 0.69, 95% CI 0.61-0.77; P < 0.00001) than never smoker (HR = 0.88, 95% CI 0.70-1.11; P = 0.28). Compared with second or later line treatment, there was better OS benefits in first line treatment subgroup (Interaction, P = 0.02). The OS benefits were similar according to age (Interaction, P = 0.74), sex (Interaction, P = 0.43), performance status (Interaction, P = 0.68), central nervous system (CNS) metastasis (Interaction, P = 0.59), tumor histology (Interaction, P = 0.64) and treatment type (Interaction, P = 0.36).
Conclusions
In conclusion, PD-L1 expression, smoking status and line of treatment were potential biomarkers for PD-1/PD-L1 inhibitors. Besides, patients > 75 years of age might not get OS benefits from this treatment. These results may improve treatment strategies and patient selection for PD-1/PD-L1 inhibitors.
Legal entity responsible for the study: Y. Weng.
Clinical trial identification
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract